Skip to main content
TipRanks
Go Ultimate75% OFF

Cordlife Group (P8A) AI Stock Analysis

3 Followers
SG:P8A

Cordlife Group

(SGX:P8A)

Select Model
Rating:44Neutral
Price Target:SGD 0.09â–¼(-3.30% Downside)
Action:reiterated
Date:10/31/26

Strong balance sheet is the primary positive factor supporting stability, while operational losses, negative cash flows, and weak technical momentum are the main drags on the score. Unattractive valuation due to unprofitability adds further pressure.

Positive Factors
Low LeverageVery low leverage and a sizable equity base reduce solvency pressure and provide financial flexibility while the company works to restore profitability. This conservative funding structure can help Cordlife sustain operations and pursue improvement without relying heavily on additional borrowing.
Negative Factors
Persistent LossesPersistent operating and net losses show that the current business model is not yet converting revenue into sustainable earnings. The deeply negative net margin can erode equity over time and limits internal funding for service development, operational investment, or expansion.

Cordlife Group (P8A) vs. iShares MSCI Singapore ETF (EWS)

-60%-40%-20%0%20%40%SG:P8A-46.78%EWS+12.47%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
SGD 32.88M
Dividend Yield
―
Average Volume (3M)
6,853
Price to Earnings (P/E)
-2.2
Beta (1Y)
0.04
Revenue Growth
―
EPS Growth
―
Country
Singapore
Employees
596
Sector
Healthcare
Sector Strength
51
Industry
Medical - Diagnostics & Research

Cordlife Group Business Overview & Revenue Model

Company Description

Established in Singapore in 2001, Cordlife Group Limited functions as an investment holding company, delivering cord blood banking solutions across a global footprint that includes Singapore, Hong Kong, India, Malaysia, and the Philippines. Its opera...

How the Company Makes Money

Cordlife primarily earns revenue by providing stem cell banking services, typically structured around (1) an upfront service fee covering enrolment, collection kits, logistics, laboratory processing, testing, and cryopreservation setup, and (2) recur...

Cordlife Group Financial Statement Overview

Summary

Strong balance sheet with minimal debt and solid equity provides stability, but volatile revenue, persistent net losses, and negative cash flows indicate ongoing operational challenges.

Income Statement

32Negative

Balance Sheet

85Very Positive

Cash Flow

24Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue36.96M38.85M27.84M55.73M55.16M56.67M
Gross Profit20.94M21.75M11.73M37.30M37.19M39.48M
EBITDA-8.60M-10.16M-14.38M8.56M9.34M10.78M
Net Income-10.69M-12.64M-18.69M3.52M4.89M6.13M
Balance Sheet
Total Assets198.87M201.76M217.14M228.46M228.00M233.71M
Cash, Cash Equivalents and Short-Term Investments49.83M51.70M60.58M65.01M65.17M64.63M
Total Debt4.32M1.34M2.42M3.50M2.22M2.97M
Total Liabilities98.61M97.28M98.68M92.81M93.67M97.02M
Stockholders Equity100.08M104.30M118.21M135.33M134.06M136.43M
Cash Flow
Free Cash Flow-981.00K-729.00K-15.62M6.96M5.32M7.93M
Operating Cash Flow-557.00K504.00K-11.31M9.80M7.71M9.50M
Investing Cash Flow10.13M2.77M-2.81M-2.63M4.43M-23.91M
Financing Cash Flow-2.91M-2.10M7.17M-1.86M-13.45M3.37M

Cordlife Group Technical Analysis

Technical Analysis SentimentNegative
Last Price0.09

Price Trends

50DMA0.12Negative
100DMA0.13Negative
200DMA0.13Negative

Market Momentum

MACD-0.01Positive
RSI7.01Positive
STOCH-0.00Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SG:P8A, the sentiment is Negative. The current price of 0.09 is below the 20-day moving average (MA) of 0.11, below the 50-day MA of 0.12, and below the 200-day MA of 0.13, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 7.01 is Positive, neither overbought nor oversold. The STOCH value of -0.00 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SG:P8A.

Cordlife Group Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

SG:P8A against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
SG:BSLSG:BSL63NeutralSGD 1.58B23.226.42%3.55%-3.18%6.71%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
SG:A50SG:A5046NeutralSGD 1.27B-40.27-6.42%―6.44%38.89%
SG:P8ASG:P8A44NeutralSGD 23.23M-2.18-10.28%―――

* Healthcare Sector Average

Performance Comparison

-50%0%50%SG:P8ASG:BSLSG:A50SG:40TSG:5WASG:TBDDDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
SG:P8A and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
SG:P8ACordlife Group 0.09-0.09-49.44%
SG:BSLRaffles Medical Group 0.84-0.12-12.80%
SG:A50Thomson Medical Group Ltd.0.05-0.01-21.67%
SG:40TISEC Healthcare Ltd0.310.000.32%
SG:5WAOUE Lippo Healthcare Limited0.050.0281.48%
SG:TBDDBangkok Dusit Medical Services Public Co Ltd Shs UnSp Singapore Depositary Receipt Repr 2/1 Sh1.520.010.86%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 31, 2026